Autoimmune disease Archives

autoimmune liver disease Genkyotex organ

News and Trends 7 Nov 2018

Solid Phase II Performance for French Autoimmune Liver Disease Drug

Genkyotex’s small molecule therapy had encouraging short-term effects on patients with the autoimmune liver disease primary biliary cholangitis in a Phase II trial. Over six weeks, the drug reduced the blood levels of a liver disease biomarker molecule by up to 23% in 92 participants. In patients with late-stage disease, who have few treatments available, […]

November 7, 2018 - 2 minutesmins - By Jonathan Smith

Sitryx immunometabolism cancer inflammation

News and Trends 8 Oct 2018

Oxford Biotech Launches with €26M to Target ‘Immunometabolism’

Sitryx has launched today with the goal of treating cancer and inflammatory conditions by targeting the metabolism of immune cells, a promising area of research. The new company has kicked off with a €26M Series A round co-led by two specialized investors, SV Health and Sofinnova Partners. Sitryx also has investment from GSK, with […]

October 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 19 Sep 2018

Argenx Attracts Huge €250M Investment Following Positive Phase II Trial

Belgian biotech Argenx raised over €250M in public investment on the Nasdaq Stock Market after announcing positive Phase II results for its lead autoimmune drug candidate. The company now plans to progress efgartigimod, an antibody fragment inspired by llama antibodies, to Phase III trials for treatment of the autoimmune blood disease primary immune thrombocytopenia (ITP). […]

September 19, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 23 Jul 2018

Sangamo Acquires French Biotech to Develop CAR-T Therapies for Autoimmune Disease

Sangamo Therapeutics has acquired TxCell with a view to utilizing its CAR-T technology to prevent organ transplant rejections and treat autoimmune disease. Sangamo, based in California, is known for bringing the first in-vivo gene therapy to the market. The company entered into an agreement to purchase TxCell for €72M. Sangamo plans to combine its zinc […]

July 23, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 3 Jul 2018

French Lupus Vaccine Ready to Move Into Phase III

Neovacs, a French biotech, has shown its lupus vaccine can be effective in treating this severe autoimmune disease. Its lupus vaccine works by stimulating the patient’s immune system to produce antibodies against a protein called IFNα that regulates the immune system and is involved in the disease. The study enrolled 185 patients around the globe […]

July 3, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 6 Jun 2018

German DNA Treatment Reduces Ulcerative Colitis Symptoms

Sterna Biologicals has obtained positive Phase IIa data for an ulcerative colitis treatment that uses DNA to inhibit inflammatory proteins, which could add to the diverse approaches being developed to treat inflammatory bowel disease. Sterna Biologicals, based in Marburg, Germany, has clinical data showing its ulcerative colitis treatment reduced the severity of the disease compared […]

June 6, 2018 - 3 minutesmins - By Alexander Burik

More News! 16 Apr 2018

Epitopes Come to the Rescue for One of the Most Common Autoimmune Diseases

The British-Belgian biotech Apitope has obtained positive Phase I results for its first-in-class treatment for Graves’ disease, one of the most common autoimmune diseases. Apitope has obtained positive clinical results indicating its treatment for Graves’ disease is safe and well-tolerated. A common autoimmune disease affecting the thyroid, Graves’ disease occurs when a patient’s immune system […]

April 16, 2018 - 2 minutesmins - By Alexander Burik

Idorsia Actelion Spin Off Jean Paul Clozel CEO

News and Trends 1 Mar 2018

How is Actelion Spin-Off Idorsia Doing One Year Later?

Actelion’s spin-off Idorsia was blessed with a large pipeline and a healthy bank balance. How has the biotech’s first year of business gone? Just over a year ago, Actelion, the largest biotech in Europe at the time, was snapped up by Johnson & Johnson for a massive €27.9Bn. “This deal is unique: J&J gets its […]

March 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

multiple sclerosis antibody CIDP geneuro 1

News and Trends 26 Feb 2018

This Multiple Sclerosis Drug Could Help to Fight Another Autoimmune Disease

The FDA has awarded Orphan Drug Designation to GeNeuro’s antibody for the treatment of a rare autoimmune disease following promising Phase IIb results in multiple sclerosis patients. GeNeuro develops therapies targeting factors encoded by human endogenous retroviruses that are implicated in neurological and autoimmune disorders. The biotech’s drug, GNbAC1, which is being developed for multiple […]

February 26, 2018 - 2 minutesmins - By Alex Dale

autoimmune disease enzyme hansa medical 1

News and Trends 19 Feb 2018

The FDA Backs a Bacterial Enzyme to Treat a Rare Autoimmune Disease

The FDA has awarded Hansa Medical’s lead candidate for the treatment of an autoimmune disease with Orphan Drug Designation, which will support its journey through clinical development. Swedish biotech, Hansa Medical, develops enzymes that can help to control the immune system for transplantations and the treatment of autoimmune diseases. The company’s lead candidate, IdeS, has […]

February 19, 2018 - 2 minutesmins - By Alex Dale

News and Trends 19 Feb 2018

Is Novartis’ Psoriasis Drug Going to Steal Humira’s Crown?

Two clinical studies have demonstrated the capacity of Novartis’ monoclonal antibody to treat both plaque and scalp psoriasis and improve patient quality of life. Not only is Novartis leading the CAR-T cell therapy field with the approval of Kymriah last year, the big pharma is also developing drugs for diseases affecting the immune system. The company presented […]

February 19, 2018 - 3 minutesmins - By Alex Dale

News and Trends 19 Feb 2018

This Belgian Biotech Gives Us an Update on its Bulging Psoriasis Pipeline

UCB has presented positive Phase IIb results for its psoriasis drug, bimekizumab, and outlined the Phase III testing of Cimzia for the condition at the American Academy of Dermatology’s annual meeting. Belgian biopharma, UCB, develops medicines for people suffering from severe diseases of the immune or central nervous systems. The company is developing a number […]

February 19, 2018 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Autoimmune disease

Solid Phase II Performance for French Autoimmune Liver Disease Drug

Oxford Biotech Launches with €26M to Target ‘Immunometabolism’

Argenx Attracts Huge €250M Investment Following Positive Phase II Trial

Sangamo Acquires French Biotech to Develop CAR-T Therapies for Autoimmune Disease

French Lupus Vaccine Ready to Move Into Phase III

German DNA Treatment Reduces Ulcerative Colitis Symptoms

Epitopes Come to the Rescue for One of the Most Common Autoimmune Diseases

How is Actelion Spin-Off Idorsia Doing One Year Later?

This Multiple Sclerosis Drug Could Help to Fight Another Autoimmune Disease

The FDA Backs a Bacterial Enzyme to Treat a Rare Autoimmune Disease

Is Novartis’ Psoriasis Drug Going to Steal Humira’s Crown?

This Belgian Biotech Gives Us an Update on its Bulging Psoriasis Pipeline

Subscribe to our newsletter to get the latest biotech news!

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!